Anlotinib: a novel targeted drug for bone and soft tissue sarcoma

S Li - Frontiers in oncology, 2021 - frontiersin.org
Bone and soft tissue sarcomas account for approximately 15% of pediatric solid malignant
tumors and 1% of adult solid malignant tumors. There are over 50 subtypes of sarcomas …

Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin

K Rejdak, H Sienkiewicz‐Jarosz… - Medicinal Research …, 2023 - Wiley Online Library
Neurotrophic factors (NTFs) are involved in the pathophysiology of neurological disorders
such as dementia, stroke and traumatic brain injury (TBI), and constitute molecular targets of …

In silico and in vitro studies for benzimidazole anthelmintics repurposing as VEGFR-2 antagonists: novel mebendazole-loaded mixed micelles with enhanced …

AA Elmaaty, KM Darwish, A Chrouda, AA Boseila… - ACS …, 2021 - ACS Publications
Cancer is a leading cause of death worldwide and its incidence is unfortunately anticipated
to rise in the next years. On the other hand, vascular endothelial growth factor receptor 2 …

An updated patent review of VEGFR-2 inhibitors (2017-present)

TA Farghaly, WA Al-Hasani… - Expert opinion on …, 2021 - Taylor & Francis
Introduction: Angiogenesis is a vital process for cellular functions in both physiological and
pathophysiological conditions and is one of the hallmarks of cancer progression and …

Design, green synthesis and tailoring of vitamin E TPGS augmented niosomal nano-carrier of pyrazolopyrimidines as potential anti-liver and breast cancer agents with …

KE Anwer, NEAA El-Sattar, MM Shamaa, MY Zakaria… - Pharmaceuticals, 2022 - mdpi.com
VEGF plays a crucial role in cancer development, angiogenesis and progression, principally
liver and breast cancer. It is vital to uncover novel chemical candidates of VEGFR inhibitors …

A phase II trial of rivoceranib, an oral vascular endothelial growth factor receptor 2 inhibitor, for recurrent or metastatic adenoid cystic carcinoma

GJ Hanna, MJ Ahn, J Muzaffar, B Keam… - Clinical Cancer …, 2023 - AACR
Purpose: This open-label, single-arm, phase II study evaluated the vascular endothelial
growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) rivoceranib in patients with …

[HTML][HTML] The role of endothelial cell–pericyte interactions in vascularization and diseases

G Li, J Gao, P Ding, Y Gao - Journal of Advanced Research, 2024 - Elsevier
Abstract Background Endothelial cells (ECs) and pericytes (PCs) are crucial components of
the vascular system, with ECs lining the inner layer of blood vessels and PCs surrounding …

Hallmarks of cancer: The insulin-like growth factors perspective

H Werner, D LeRoith - Frontiers in Oncology, 2022 - frontiersin.org
The identification of a series of attributes or hallmarks that are shared by virtually all cancer
cells constitutes a true milestone in cancer research. The conceptualization of a catalogue of …

NGF prevents loss of TrkA/VEGFR2 cells, and VEGF isoform dysregulation in the retina of adult diabetic rats

E Fico, P Rosso, V Triaca, M Segatto, A Lambiase… - Cells, 2022 - mdpi.com
Among the factors involved in diabetic retinopathy (DR), nerve growth factor (NGF) and
vascular endothelial growth factor A (VEGFA) have been shown to affect both neuronal …

Brown adipose tissue as an endocrine organ: updates on the emerging role of batokines

FF Martins, V Souza-Mello, MB Aguila… - … Molecular Biology and …, 2023 - degruyter.com
Brown adipose tissue (BAT) remains active in adults, oxidizing fatty acids or glucose and
releasing energy in the form of heat. Brown adipocytes and enhanced thermogenesis are …